GSK plc (GSK) Stock Competitors & Peer Comparison
See (GSK) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GSK | $51.49 | +1.68% | 103B | 13.52 | $3.79 | +3.53% |
| LLY | $1,156.69 | +0.66% | 1.1T | 40.61 | $28.17 | +0.56% |
| JNJ | $239.98 | +3.37% | 570.7B | 27.44 | $8.64 | +2.21% |
| ABBV | $226.60 | +1.58% | 398.2B | 109.93 | $2.05 | +2.98% |
| MRK | $119.04 | -0.40% | 295.3B | 33.68 | $3.55 | +2.76% |
| NVS | $149.58 | +2.16% | 284.5B | 21.36 | $6.98 | +3.17% |
| AZN | $181.17 | -0.21% | 284.4B | 27.61 | $6.64 | +1.74% |
| AMGN | $347.74 | +0.58% | 186B | 23.98 | $14.37 | +2.85% |
| GILD | $123.11 | -3.90% | 155.8B | 14.99 | $8.37 | +2.54% |
| PFE | $25.79 | +0.67% | 146.3B | 19.60 | $1.31 | +6.68% |
Stock Comparison
GSK vs LLY Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, GSK is priced at $51.49, while LLY trades at $1,156.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas LLY's P/E ratio is 40.61. In terms of profitability, GSK's ROE is +0.28%, compared to LLY's ROE of +1.01%. Regarding short-term risk, GSK is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check LLY's competition here
GSK vs JNJ Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, JNJ has a market cap of 570.7B. Regarding current trading prices, GSK is priced at $51.49, while JNJ trades at $239.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas JNJ's P/E ratio is 27.44. In terms of profitability, GSK's ROE is +0.28%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, GSK is less volatile compared to JNJ. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check JNJ's competition here
GSK vs ABBV Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, ABBV has a market cap of 398.2B. Regarding current trading prices, GSK is priced at $51.49, while ABBV trades at $226.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas ABBV's P/E ratio is 109.93. In terms of profitability, GSK's ROE is +0.28%, compared to ABBV's ROE of +0.68%. Regarding short-term risk, GSK is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check ABBV's competition here
GSK vs MRK Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, MRK has a market cap of 295.3B. Regarding current trading prices, GSK is priced at $51.49, while MRK trades at $119.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas MRK's P/E ratio is 33.68. In terms of profitability, GSK's ROE is +0.28%, compared to MRK's ROE of +0.18%. Regarding short-term risk, GSK is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check MRK's competition here
GSK vs NVS Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, NVS has a market cap of 284.5B. Regarding current trading prices, GSK is priced at $51.49, while NVS trades at $149.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas NVS's P/E ratio is 21.36. In terms of profitability, GSK's ROE is +0.28%, compared to NVS's ROE of +0.32%. Regarding short-term risk, GSK is less volatile compared to NVS. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check NVS's competition here
GSK vs AZN Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, AZN has a market cap of 284.4B. Regarding current trading prices, GSK is priced at $51.49, while AZN trades at $181.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas AZN's P/E ratio is 27.61. In terms of profitability, GSK's ROE is +0.28%, compared to AZN's ROE of +0.22%. Regarding short-term risk, GSK is less volatile compared to AZN. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check AZN's competition here
GSK vs AMGN Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, AMGN has a market cap of 186B. Regarding current trading prices, GSK is priced at $51.49, while AMGN trades at $347.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas AMGN's P/E ratio is 23.98. In terms of profitability, GSK's ROE is +0.28%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, GSK is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check AMGN's competition here
GSK vs GILD Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, GILD has a market cap of 155.8B. Regarding current trading prices, GSK is priced at $51.49, while GILD trades at $123.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas GILD's P/E ratio is 14.99. In terms of profitability, GSK's ROE is +0.28%, compared to GILD's ROE of +0.42%. Regarding short-term risk, GSK is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check GILD's competition here
GSK vs PFE Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, PFE has a market cap of 146.3B. Regarding current trading prices, GSK is priced at $51.49, while PFE trades at $25.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas PFE's P/E ratio is 19.60. In terms of profitability, GSK's ROE is +0.28%, compared to PFE's ROE of +0.08%. Regarding short-term risk, GSK is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check PFE's competition here
GSK vs BMY Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, BMY has a market cap of 115.3B. Regarding current trading prices, GSK is priced at $51.49, while BMY trades at $56.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas BMY's P/E ratio is 15.82. In terms of profitability, GSK's ROE is +0.28%, compared to BMY's ROE of +0.39%. Regarding short-term risk, GSK is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check BMY's competition here
GSK vs SNY Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, SNY has a market cap of 107.7B. Regarding current trading prices, GSK is priced at $51.49, while SNY trades at $43.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas SNY's P/E ratio is 19.45. In terms of profitability, GSK's ROE is +0.28%, compared to SNY's ROE of +0.11%. Regarding short-term risk, GSK is less volatile compared to SNY. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check SNY's competition here
GSK vs ZTS Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, ZTS has a market cap of 34.4B. Regarding current trading prices, GSK is priced at $51.49, while ZTS trades at $81.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas ZTS's P/E ratio is 13.46. In terms of profitability, GSK's ROE is +0.28%, compared to ZTS's ROE of +0.62%. Regarding short-term risk, GSK is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check ZTS's competition here
GSK vs BIIB Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, BIIB has a market cap of 29.4B. Regarding current trading prices, GSK is priced at $51.49, while BIIB trades at $199.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas BIIB's P/E ratio is 21.41. In terms of profitability, GSK's ROE is +0.28%, compared to BIIB's ROE of +0.08%. Regarding short-term risk, GSK is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check BIIB's competition here
GSK vs HZNP Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, GSK is priced at $51.49, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas HZNP's P/E ratio is 61.86. In terms of profitability, GSK's ROE is +0.28%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, GSK is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check HZNP's competition here
GSK vs GRFS Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, GRFS has a market cap of 6.2B. Regarding current trading prices, GSK is priced at $51.49, while GRFS trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas GRFS's P/E ratio is 10.34. In terms of profitability, GSK's ROE is +0.28%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, GSK is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check GRFS's competition here
GSK vs OGN Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, OGN has a market cap of 3.5B. Regarding current trading prices, GSK is priced at $51.49, while OGN trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas OGN's P/E ratio is 14.41. In terms of profitability, GSK's ROE is +0.28%, compared to OGN's ROE of +0.30%. Regarding short-term risk, GSK is more volatile compared to OGN. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check OGN's competition here
GSK vs CELG-RI Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, CELG-RI has a market cap of 219.5M. Regarding current trading prices, GSK is priced at $51.49, while CELG-RI trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.28%, compared to CELG-RI's ROE of +0.39%. Regarding short-term risk, GSK is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check CELG-RI's competition here
GSK vs CTOR Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, CTOR has a market cap of 64.6M. Regarding current trading prices, GSK is priced at $51.49, while CTOR trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas CTOR's P/E ratio is -1.45. In terms of profitability, GSK's ROE is +0.28%, compared to CTOR's ROE of -0.99%. Regarding short-term risk, GSK is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check CTOR's competition here
GSK vs SCLX Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, SCLX has a market cap of 59.8M. Regarding current trading prices, GSK is priced at $51.49, while SCLX trades at $7.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas SCLX's P/E ratio is -0.17. In terms of profitability, GSK's ROE is +0.28%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, GSK is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check SCLX's competition here
GSK vs MIRA Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, MIRA has a market cap of 41M. Regarding current trading prices, GSK is priced at $51.49, while MIRA trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas MIRA's P/E ratio is -0.77. In terms of profitability, GSK's ROE is +0.28%, compared to MIRA's ROE of -1.41%. Regarding short-term risk, GSK is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check MIRA's competition here
GSK vs SRXH Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, SRXH has a market cap of 4.1M. Regarding current trading prices, GSK is priced at $51.49, while SRXH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas SRXH's P/E ratio is -0.71. In terms of profitability, GSK's ROE is +0.28%, compared to SRXH's ROE of +8.75%. Regarding short-term risk, GSK is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check SRXH's competition here
GSK vs SCLXW Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, SCLXW has a market cap of 1.4M. Regarding current trading prices, GSK is priced at $51.49, while SCLXW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas SCLXW's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.28%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, GSK is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check SCLXW's competition here
GSK vs CRXT Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, GSK is priced at $51.49, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas CRXT's P/E ratio is -0.02. In terms of profitability, GSK's ROE is +0.28%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, GSK is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check CRXT's competition here
GSK vs BDSIW Comparison June 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 103B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, GSK is priced at $51.49, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 13.52, whereas BDSIW's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.28%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, GSK is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check BDSIW's competition here